Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...
HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...
The U.S. Food and Drug Administration has approved the first biosimilar form of insulin for adults with diabetes type 2, and adults and pediatric patients with diabetes type 1. Semglee (insulin ...
June 27 2010 (Orlando, Florida) — Once-weekly exenatide was better at lowering glycosylated hemoglobin (HbA1c) levels in patients with type 2 diabetes in 2 randomized trials — DURATION-2 and ...
TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback